货号:A316723
同义名:
AC480 Hydrochloride; BMS-599626 Hydrochloride
BMS-599626 HCl是一种 HER1 和 HER2 双重抑制剂,IC50 分别为 20 nM 和 30 nM,对 HER4 的选择性较低,显示出良好的抗肿瘤活性。


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} {[ size_append(item.pr_size_append, item.pr_am, item.pr_size) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | EGFR/ErbB1 ↓ ↑ | ErbB3 ↓ ↑ | ErbB4 ↓ ↑ | HER2/ErbB2 ↓ ↑ | mutant EGFR ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WZ-3146 |
++++
EGFR (E746_A750/T790M), IC50: 14 nM EGFR (E746_A750), IC50: 2 nM |
99%+ | |||||||||||||||||
| Daphnetin |
+
EGFR, IC50: 7.67 μM |
PKA,PKC | 95% | ||||||||||||||||
| Lifirafenib |
++
EGFR, IC50: 29 nM |
+
EGFR(T790M/L858R), IC50: 495 nM |
98% | ||||||||||||||||
| PD168393 |
++++
EGFR, IC50: 0.70 nM |
99%+ | |||||||||||||||||
| Nazartinib |
++
mutant EGFR, Ki: 0.031 μM |
++
mutant EGFR, Ki: 0.031 μM |
98% | ||||||||||||||||
| Norcantharidin | ✔ | 98% | |||||||||||||||||
| CL-387785 |
++++
EGFR, IC50: 370 pM |
98% | |||||||||||||||||
| WHI-P154 |
+++
EGFR, IC50: 4 nM |
Src,VEGFR | 98% | ||||||||||||||||
| Tyrphostin A9 |
+
EGFR, IC50: 460 μM |
PDGFR | 98% | ||||||||||||||||
| AG 555 |
+
EGFR, IC50: 0.7 μM |
98% | |||||||||||||||||
| AG 494 |
+
EGFR, IC50: 1.2 μM |
99%+ | |||||||||||||||||
| AG-556 |
+
EGFR, IC50: 5 μM |
98% | |||||||||||||||||
| RG13022 |
+
EGFR, IC50: 4 μM |
99%+ | |||||||||||||||||
| Tyrphostin RG 14620 | ✔ | 99%+ | |||||||||||||||||
| Vandetanib |
+
EGFR, IC50: 500 nM |
99% | |||||||||||||||||
| CNX-2006 |
++
mutant EGFR, IC50: <20 nM |
++
mutant EGFR, IC50: <20 nM |
99% | ||||||||||||||||
| AZD3759 |
++++
EGFR (WT), IC50: 0.3 nM EGFR (L858R), IC50: 0.2 nM |
98% | |||||||||||||||||
| Erlotinib |
++++
EGFR, IC50: 2 nM |
95% | |||||||||||||||||
| Saracatinib |
+++
EGFR, IC50: 5 nM EGFR (L861Q), IC50: 4 nM |
99%+ | |||||||||||||||||
| AG1557 | ✔ | 99% | |||||||||||||||||
| Rociletinib |
++
EGFR (wt), Ki: 303.3 nM EGFR (L858R/T790M), Ki: 21.5 nM |
98% | |||||||||||||||||
| AG490 |
+
EGFR, IC50: 0.1 μM |
98% | |||||||||||||||||
| Cetuximab |
++++
EGFR, Kd: 0.39 nM |
95% | |||||||||||||||||
| Osimertinib |
++
L858R/T790M EGFR, IC50: 11.44 nM WT EGFR, IC50: 12.92 nM |
98% | |||||||||||||||||
| Osimertinib mesylate | ✔ | 98% (Content MsOH 15.2-18.2%) | |||||||||||||||||
| Chrysophanol | ✔ | mTOR | 98% | ||||||||||||||||
| PD153035 |
++++
EGFR, Ki: 5.2 pM |
99%+ | |||||||||||||||||
| Olmutinib | ✔ | BTK | 99%+ | ||||||||||||||||
| WZ4002 |
++++
EGFR (L858R/T790M), IC50: 8 nM EGFR (L858R), IC50: 2 nM |
99%+ | |||||||||||||||||
| Icotinib |
+++
EGFR, IC50: 5 nM |
99% | |||||||||||||||||
| Desmethyl Erlotinib HCl |
++++
EGFR, IC50: 2 nM |
98% | |||||||||||||||||
| Cyasterone | ✔ | 99%+ | |||||||||||||||||
| PP 3 |
+
EGFR tyrosine kinase, IC50: 2.7 μM |
98% | |||||||||||||||||
| WZ8040 | ✔ | 99%+ | |||||||||||||||||
| (-)-Epigallocatechin Gallate | ✔ | 99% | |||||||||||||||||
| AG 18 |
+
EGFR, IC50: 35 μM |
99%+ | |||||||||||||||||
| O-Desmethyl gefitinib |
++
EGFR, IC50: 36 nM |
99% | |||||||||||||||||
| Falnidamol | ✔ | 99%+ | |||||||||||||||||
| AZ-5104 |
++++
EGFR (L861Q) , IC50: <1 nM EGFR (L858R), IC50: 6 nM |
+++
ErbB4, IC50: 7 nM |
BRK | 99%+ | |||||||||||||||
| Butein | ✔ | 95% | |||||||||||||||||
| Genistein | ✔ | 98% | |||||||||||||||||
| SU5214 |
+
EGFR, IC50: 36.7 μM |
99%+ | |||||||||||||||||
| Naquotinib | ✔ | 99%+ | |||||||||||||||||
| Gefitinib |
++
EGFR, IC50: 15.5 nM |
+
EGFR (858R/T790M), IC50: 823.3 nM |
98% | ||||||||||||||||
| Theliatinib |
+++
WT EGFR, IC50: 3 nM |
++
EGFR T790M/L858R, IC50: 22 nM |
99% | ||||||||||||||||
| Lazertinib |
++++
L858R/T790M EGFR, IC50: 2 nM WT EGFR, IC50: 76 nM |
++++
Del19/T790M, IC50: 1.7 nM |
99%+ | ||||||||||||||||
| Gefitinib-based PROTAC 3 |
++
EGFR, DC50: 22.3 nM |
99%+ | |||||||||||||||||
| MTX-211 | ✔ | PI3K | 98% | ||||||||||||||||
| (E)-AG 99 | ✔ | 99%+ | |||||||||||||||||
| Licochalcone D | ✔ | Caspase,PARP | 99% | ||||||||||||||||
| Zipalertinib |
+++
EGFR (L861Q), IC50: 4.1 nM EGFR WT, IC50: 8 nM |
+++
HER4, IC50: 4 nM |
++++
EGFR L858R, IC50: 2 nM EGFR(d746-750), IC50: 1.4 nM |
97% | |||||||||||||||
| JND3229 |
+++
EGFR WT, IC50: 6.8 nM |
++
EGFR L858R/T790M, IC50: 30.5 nM |
99%+ | ||||||||||||||||
| Firmonertinib mesylate | ✔ | 99%+ | |||||||||||||||||
| Tyrphostin AG30 | ✔ | 99%+ | |||||||||||||||||
| EGFR-IN-12 |
++
EGFR, IC50: 21 nM |
99%+ | |||||||||||||||||
| Mobocertinib | ✔ | 98% | |||||||||||||||||
| (Rac)-JBJ-04-125-02 | ✔ | 95% | |||||||||||||||||
| (S)-Sunvozertinib | ✔ | 99% | |||||||||||||||||
| BLU-945 | ✔ | 95% | |||||||||||||||||
| Poziotinib |
+++
HER1, IC50: 3.2 nM |
++
HER4, IC50: 23.5 nM |
+++
HER2, IC50: 5.3 nM |
98% | |||||||||||||||
| TAK-285 |
++
EGFR/HER1, IC50: 23 nM |
+
HER4, IC50: 260 nM |
++
HER2, IC50: 17 nM |
99%+ | |||||||||||||||
| ARRY-380 analog | ✔ | 99% | |||||||||||||||||
| Canertinib |
++++
EGFR, IC50: 1.5 nM |
+++
ErbB2, IC50: 9.0 nM |
99%+ | ||||||||||||||||
| Dacomitinib |
+++
EGFR, IC50: 6.0 nM |
+
ErbB4, IC50: 73.7 nM |
+
ErbB2, IC50: 45.7 nM |
98% | |||||||||||||||
| EGFR/ErbB-2/ErbB-4 inhibitor-2 |
+
ErbB4, IC50: 1.91 μM |
+
ErbB2, IC50: 0.08 μM |
99%+ | ||||||||||||||||
| (E/Z)-CP-724714 |
++
HER2/ErbB2, IC50: 10 nM |
95% | |||||||||||||||||
| Lapatinib |
++
EGFR, IC50: 10.8 nM |
+
ErbB4, IC50: 367 nM |
+++
ErbB2, IC50: 9.2 nM |
98% | |||||||||||||||
| AEE788 |
++++
EGFR, IC50: 2 nM |
+
HER4/ErbB4, IC50: 160 nM |
+++
HER2/ErbB2, IC50: 6 nM |
c-Fms/CSF1R | 98+% | ||||||||||||||
| AV-412 free base |
++++
EGFR, IC50: 0.75 nM |
++
ErbB2, IC50: 19 nM |
++++
EGFRT790M, IC50: 0.79 nM EGFRL858R/T790M, IC50: 0.51 nM |
98+% | |||||||||||||||
| Neratinib |
+
EGFR, IC50: 92 nM |
+
HER2, IC50: 59 nM |
Src | 98% | |||||||||||||||
| BMS-599626 |
++
HER1, IC50: 20 nM |
+
HER4, IC50: 190 nM |
++
HER2, IC50: 30 nM |
98% | |||||||||||||||
| Tucatinib |
+++
ErbB2, IC50: 8 nM |
98% | |||||||||||||||||
| Allitinib |
++++
EGFR, IC50: 0.5 nM |
++++
ErbB4, IC50: 0.8 nM |
+++
ErbB2, IC50: 3.0 nM |
99% | |||||||||||||||
| Pelitinib |
+
EGFR, IC50: 38.5 nM |
+
ErbB2, IC50: 1.255 μM |
Src,Raf | 99%+ | |||||||||||||||
| Sapitinib |
+++
EGFR, IC50: 4 nM |
+++
ErbB3, IC50: 4 nM |
+++
ErbB2, IC50: 3 nM |
99%+ | |||||||||||||||
| CUDC-101 |
+++
EGFR, IC50: 2.4 nM |
++
HER2, IC50: 15.7 nM |
HDAC | 99%+ | |||||||||||||||
| Varlitinib |
+++
ErbB1, IC50: 7 nM |
++++
ErbB2, IC50: 2 nM |
99%+ | ||||||||||||||||
| Afatinib dimaleate |
++++
EGFR (L858R/T790M), IC50: 0.4 nM EGFR (wt), IC50: 0.5 nM |
++
HER2, IC50: 14 nM |
98% | ||||||||||||||||
| Canertinib 2HCl |
+++
EGFR, IC50: 7.4 nM |
+++
ErbB2, IC50: 9 nM |
99% | ||||||||||||||||
| Allitinib tosylate |
++++
EGFR, IC50: 0.5 nM EGFR (T790M/L858R), IC50: 12 nM |
++++
ErbB4, IC50: 0.8 nM |
+++
ErbB2, IC50: 3.0 nM |
99% | |||||||||||||||
| Tyrphostin AG 528 |
+
EGFR, IC50: 4.9 μM |
+
HER2, IC50: 2.1 μM |
97% | ||||||||||||||||
| Afatinib |
++++
EGFR (wt), IC50: 0.5 nM EGFR (L858R), IC50: 10 nM |
++++
ErbB4, IC50: 1 nM |
++
HER2, IC50: 14 nM |
99% | |||||||||||||||
| Pyrotinib dimaleate |
++
EGFR, IC50: 0.013 μM |
++
HER2, IC50: 0.038 μM |
98% | ||||||||||||||||
| Epertinib HCl |
++++
EGFR, IC50: 1.48 nM |
+++
HER4, IC50: 2.49 nM |
+++
HER2, IC50: 7.15 nM |
99% | |||||||||||||||
| Tuxobertinib |
++++
EGFR, Kd: 0.2 nM |
++++
HER2, Kd: 0.76 nM |
99% | ||||||||||||||||
| ALK-IN-1 |
++
EGFR(del19), IC50: 36.8 nM EGFR(C797S/del19), IC50: 138.6 nM |
ALK | 99% | ||||||||||||||||
| Brigatinib |
+
EGFR(del19), IC50: 39.9 nM EGFR(C797S/T790M/del19), IC50: 67.2 nM |
ALK,FLT3 | 98% | ||||||||||||||||
| Avitinib |
++++
EGFR L858R/T790M, IC50: 0.18 nM |
BTK | 99%+ | ||||||||||||||||
| EAI045 | ✔ | 97% | |||||||||||||||||
| Almonertinib | ✔ | 99% | |||||||||||||||||
| BI-4020 |
++++
EGFRdel19 T790M C797S, IC50: 0.2 nM |
99%+ | |||||||||||||||||
| EGFR-IN-7 |
++++
EGFRd746-750/T790M/C797S, IC50: 0.26 nM EGFRL858R/T790M, IC50: 0.19 nM |
99% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | HER2 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Poziotinib |
++++
HER2, IC50: 5.3 nM |
98% | |||||||||||||||||
| Tyrphostin AG 879 |
+
HER2-Neu, IC50: 1.0 μM |
95% | |||||||||||||||||
| TAK-285 |
+
HER2, IC50: 17 nM |
99%+ | |||||||||||||||||
| ARRY-380 analog | ✔ | 99% | |||||||||||||||||
| Canertinib |
+++
ErbB2, IC50: 9.0 nM |
EGFR | 99%+ | ||||||||||||||||
| (E/Z)-CP-724714 |
++
HER2/ErbB2, IC50: 10 nM |
95% | |||||||||||||||||
| Lapatinib |
+++
ErbB2, IC50: 9.2 nM |
EGFR | 98% | ||||||||||||||||
| AEE788 |
++++
HER2/ErbB2, IC50: 6 nM |
EGFR | 98+% | ||||||||||||||||
| Neratinib |
+
HER2, IC50: 59 nM |
Src,EGFR | 98% | ||||||||||||||||
| BMS-599626 |
+
HER2, IC50: 30 nM |
98% | |||||||||||||||||
| Mubritinib |
++++
HER2/ErbB2, IC50: 6.0 nM |
99%+ | |||||||||||||||||
| Tucatinib |
+++
ErbB2, IC50: 8 nM |
98% | |||||||||||||||||
| Sapitinib |
++++
ErbB2, IC50: 3 nM |
EGFR | 99%+ | ||||||||||||||||
| CUDC-101 |
++
HER2, IC50: 15.7 nM |
HDAC,EGFR | 99%+ | ||||||||||||||||
| Afatinib dimaleate |
++
HER2, IC50: 14 nM |
98% | |||||||||||||||||
| Afatinib |
++
HER2, IC50: 14 nM |
99% | |||||||||||||||||
| Pertuzumab | ✔ | 95% | |||||||||||||||||
| Trastuzumab | ✔ | 99% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | BMS-599626 is a selective and efficacious inhibitor of HER1 and HER2 with IC50 of 20 nM and 30 nM, ~8-fold less potent to HER4, > 100-fold to VEGFR2, c-Kit, Lck, MET etc. |
| Concentration | Treated Time | Description | References | |
| OV202 ovarian cancer cells | 10 μM | 1 hour | To evaluate the effect of BMS-599626 on HER2 phosphorylation, results showed that BMS-599626 reduced HER2 phosphorylation | Mol Cancer Ther. 2008 Sep;7(9):2589-98 |
| HNSCC cell lines | 5 μM | 72 h | To evaluate the synergistic growth inhibition and apoptotic effects of BMS599626 in combination with BMS754807 on HNSCC cell lines. Results showed synergistic apoptosis in UNC7 cells and additive apoptosis in UNC10 cells. | Head Neck. 2015 Dec;37(12):1722-32 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.76mL 0.35mL 0.18mL |
8.82mL 1.76mL 0.88mL |
17.64mL 3.53mL 1.76mL |
|
| CAS号 | 873837-23-1 |
| 分子式 | C27H28ClFN8O3 |
| 分子量 | 567.01 |
| SMILES Code | O=C(OC[C@H]1NCCOC1)NC2=CN3N=CN=C(NC4=CC5=C(N(CC6=CC=CC(F)=C6)N=C5)C=C4)C3=C2C.[H]Cl |
| MDL No. | MFCD12407406 |
| 别名 | AC480 Hydrochloride; BMS-599626 Hydrochloride |
| 运输 | 蓝冰 |
| InChI Key | COUSSRGSHIJMMN-FTBISJDPSA-N |
| Pubchem ID | 46930994 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry,2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(185.18 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1